News Category
Quantum BioPharma's agreement with Thermo Fisher's clinical research business to launch a Phase 2 trial of Lucid-MS marks a pivotal step for a neuropr...
VERAXA Biotech is implementing FDA-aligned New Approach Methodologies to accelerate preclinical development, cut costs, and significantly reduce anima...
Lantern Pharma receives Taiwan regulatory and IRB approvals to open Part 2 of its Phase 2 HARMONIC trial, potentially accelerating development of LP-3...
Quantum BioPharma has signed a Study Start-Up Agreement with Thermo Fisher Scientific's clinical research business to implement a Phase 2 trial of its...
VERAXA Biotech (NASDAQ: VRXA) is implementing FDA-aligned New Approach Methodologies to reduce animal testing, potentially accelerating clinical advan...
XORTX Therapeutics is positioning its XORLO gout treatment for an FDA new drug application within a year, aiming to address the limitations of current...
A new study reveals lymph node-like structures in the skull that could enable localized immune responses against brain diseases, potentially transform...
Creative Bioarray's comprehensive in vitro ADME services provide early data on drug candidates' absorption, distribution, metabolism, and elimination,...
GeoVax's next-generation MVA-X vaccine demonstrated durable single-dose protection against lethal mpox, including Clade I, and durable CD8+ T-cell res...
Onco-Innovations is integrating manufacturing, preclinical, and regulatory activities for its lead cancer candidate ONC010, aiming to move it toward f...
VERAXA Biotech has named Raju Willener as CFO, bringing over 30 years of capital markets experience as the company advances its BiTAC oncology pipelin...
Apimeds Pharmaceuticals US, Inc. has engaged IBN for corporate communications to raise awareness of its biopharmaceutical and blockchain infrastructur...
Regentis Biomaterials is advancing its GelrinC cartilage repair treatment through a U.S. pivotal trial and European commercialization, targeting a 470...
Silo Pharma's U.S. patent allowance for SPC-15 strengthens its intellectual property position in developing a novel intranasal treatment for post-trau...
Regentis Biomaterials is developing GelrinC, an off-the-shelf hydrogel implant that could regenerate knee cartilage, addressing a major unmet need for...
Med-X is expanding its Nature-Cide natural pest-control line with OMRI certification and commercial growth initiatives as it prepares for a Nasdaq lis...
Telomir Pharmaceuticals reports that its lead compound Telomir-Zn inhibited growth in human and canine osteosarcoma cell lines at similar low concentr...
Quantum BioPharma's FDA clearance of its IND for Lucid-MS enables a Phase 2 trial in multiple sclerosis, potentially advancing a novel treatment that ...
GeoVax's agreement with CEPI to use its Centralised Laboratory Network for the GEO-MVA Phase 3 trial aims to generate independent, standardized data t...
Preclinical research published in Science Advances demonstrates that engineered suppressor tRNAs can restore full-length dystrophin and improve muscle...
Creative Biolabs has expanded its functionalized lipid-based delivery system development capabilities, offering customized targeted and stimuli-respon...
Creative Biolabs has upgraded its single-cell multi-omics and RNA sequencing services to meet growing demand for high-resolution cellular profiling, e...
A new review reveals that the tumor microenvironment actively sculpts natural killer cells into distinct subsets with specialized functions, offering ...
GeoVax Labs is appealing a Nasdaq delisting determination while continuing to advance its GEO-MVA vaccine for mpox and smallpox and its oncology thera...
Regentis Biomaterials reported first half 2026 financial results, highlighted progress in its Phase III GelrinC trial, and announced a 400% production...
Quantum BioPharma's FDA clearance for a Phase 2 trial of Lucid-MS represents a potential paradigm shift in multiple sclerosis treatment by targeting m...
TransCode Therapeutics has named John Tattory as interim CFO after Tom Fitzgerald's retirement, bringing extensive financial leadership to the clinica...
VERAXA Biotech's appointment of Dr. Christoph Erkel as CSO signals a strategic push to advance its BiTAC® T-cell engager and broader oncology pipeline...
Quantum BioPharma's Lucid-MS, a first-in-class PAD2 inhibitor, has received FDA clearance to begin a Phase 2 trial in multiple sclerosis, potentially ...
Quantum BioPharma's FDA clearance to launch a phase 2 trial of Lucid-MS, a first-in-class myelin-repair therapy for multiple sclerosis, represents a h...
Quantum BioPharma receives FDA clearance to launch a phase 2 trial of Lucid-MS, a first-in-class multiple sclerosis drug designed to protect and rebui...
Helus Pharma's CEO will present at the Morgan Stanley Global Healthcare Conference, highlighting the company's advanced clinical programs for depressi...
Onco-Innovations' CMO Dr. Islam Mohamed detailed the company's novel PNKP-targeting drug candidate ONC010 on the BioMedWire podcast, emphasizing its p...
Quantum BioPharma's Lucid-MS, a first-in-class non-covalent PAD2 inhibitor, is moving toward a Phase 2 trial for multiple sclerosis following FDA clea...
American Fusion Inc. has transitioned its Texatron fusion program from prototype development to active testing, reporting peak confinement pressures o...
Kairos Pharma's CEO will present at the H.C. Wainwright conference, underscoring the company's innovative approach to tackling cancer drug resistance ...
Nutriband CEO Gareth Sheridan's attendance at the Nasdaq LaB summit highlights the company's strategic engagement with investors and industry leaders,...
Silo Pharma's participation in the IPAC-RS 2026 Nasal Innovation Forum underscores its commitment to advancing SPC-15, a nose-to-brain therapy for PTS...
Quantum BioPharma's FDA clearance for Lucid-MS Phase 2 trial marks a pivotal milestone in developing a first-in-class therapy that could repair myelin...
Quantum BioPharma's Lucid-MS, a first-in-class myelin-protective multiple sclerosis drug candidate, has received FDA clearance to begin a Phase 2 tria...
Helus Pharma's CEO participation in a major investment conference underscores the company's advancing clinical pipeline for mental health treatments.
GeoVax supports the new global mpox vaccine stockpile and emphasizes its GEO-MVA candidate's readiness to bolster diversified vaccine supply.
Voyageur Pharmaceuticals has achieved a key milestone under its collaboration with Bayer, securing a $1 million payment to advance a domestic iodine p...
Greenland Mines is spinning off its biotech division to become a pure-play critical minerals company, highlighted by the acquisition of the Sarfartoq ...
VERAXA Biotech's appointment of seasoned financial executive Raju Willener as CFO underscores its commitment to advancing its BiTAC platform and oncol...
Scinai Immunotherapeutics strategically shifts its R&D focus to its NanoAb platform and CDMO business after terminating its PC111 license with PinCell...
Onco-Innovations advances its oncology pipeline by building manufacturing capabilities, IND-enabling activities, and capital foundation ahead of plann...
OS Animal Health, a subsidiary of OS Therapies, will present its lead candidate OST-HER2 for canine osteosarcoma at the 2026 Disruptive Growth & Life ...
